摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

| 1443740-20-2

中文名称
——
中文别名
——
英文名称
——
英文别名
——
化学式
CAS
1443740-20-2
化学式
C18H20N4O2S
mdl
——
分子量
356.448
InChiKey
KKCGRPNNGPQXLE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.0
  • 重原子数:
    25.0
  • 可旋转键数:
    5.0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    69.9
  • 氢给体数:
    0.0
  • 氢受体数:
    7.0

反应信息

  • 作为反应物:
    描述:
    、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 、 lithium hydroxide 作用下, 以 四氢呋喃1,4-二氧六环二氯甲烷 为溶剂, 反应 16.0h, 生成 5-(butan-2-yl)-1-[5-methyl-4-(2-thienyl)pyrimidin-2-yl]-N-(pyridin-4-ylmethyl)-1H-pyrazole-4-carboxamide
    参考文献:
    名称:
    Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes
    摘要:
    GPR142 is a G protein-coupled receptor that is predominantly expressed in pancreatic beta-cells. GPR142 agonists stimulate insulin secretion in the presence of high glucose concentration, so that they could be novel insulin secretagogues with reduced or no risk of hypoglycemia. We report here the optimization of HTS hit compound 1 toward a proof of concept compound 33, which showed potent glucose lowering effects during an oral glucose tolerance test in mice and monkeys.
    DOI:
    10.1021/ml400186z
  • 作为产物:
    描述:
    2,4-二氯-5-甲基嘧啶吡啶四(三苯基膦)钯potassium carbonate溶剂黄146 作用下, 以 乙二醇二甲醚乙醇 为溶剂, 反应 25.0h, 生成
    参考文献:
    名称:
    Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes
    摘要:
    GPR142 is a G protein-coupled receptor that is predominantly expressed in pancreatic beta-cells. GPR142 agonists stimulate insulin secretion in the presence of high glucose concentration, so that they could be novel insulin secretagogues with reduced or no risk of hypoglycemia. We report here the optimization of HTS hit compound 1 toward a proof of concept compound 33, which showed potent glucose lowering effects during an oral glucose tolerance test in mice and monkeys.
    DOI:
    10.1021/ml400186z
点击查看最新优质反应信息